SCHEMBL4082470

SCHEMBL4082470

Nc1ccc(CS(=O)(=O)c2ccccc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.61
TSHR P16473 1/20 0.53
HSD17B10 Q99714 1/20 0.53
GAA P10253 1/20 0.48
MAOB P27338 4/20 0.48
MAOA P21397 2/20 0.48
PSIP1 O75475 2/20 0.48
KEAP1 Q14145 1/20 0.47
HTR6 P50406 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA5A P35218 1/20 0.47
CA9 Q16790 1/20 0.47
PRMT1 Q99873 1/20 0.45
CYP2D6 P10635 1/20 0.44
LOXL2 Q9Y4K0 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5081823 0.92 TSHR (0.62) MAPTTSHRHSD17B10GAAMAOB
SCHEMBL18868426 0.90 GAA (0.59) MAPTTSHRHSD17B10GAAPSIP1
Benzylsulfonylbenzene SCHEMBL780337 0.85 TSHR (0.68) MAPTTSHRHSD17B10PSIP1KEAP1
Benzylsulfonylbenzene SCHEMBL1877584 0.83 TSHR (0.66) MAPTTSHRHSD17B10PSIP1KEAP1
SCHEMBL11331449 0.82 CA2 (0.65) MAPTTSHRGAACA1CA2
SCHEMBL3381366 0.81 GAA (0.55) MAPTTSHRGAAPSIP1HTR6
SCHEMBL7082360 0.81 CYP3A4 (0.47) MAPTTSHRHSD17B10GAAPSIP1
SCHEMBL6509990 0.81 MAOB (0.57) GAAMAOBMAOAPSIP1KEAP1
SCHEMBL30963220 0.81 MEN1 (0.60) TSHRGAAPSIP1HTR6CA1
SCHEMBL11114440 0.80 MAPT (0.61) MAPTTSHRHSD17B10PSIP1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203585-A1 CAPREOMYCIN DERIVATIVES AND THEIR USE AS ANTIBACTERIALS ARRAY BIOPHARMA, INC. 2009-08-13 US disclosed
WO-2007130743-A2 CAPREOMYCIN DERIVATIVES AND THEIR USE AS ANTIBACTERIALS ARRAY BIOPHARMA, INC. (US) 2007-11-15 WO disclosed
US-7294616-B2 Capreomycin derivatives and their use as antibacterials ARRAY BIOPHARMA, INC. (US) 2007-11-13 US disclosed
WO-2006052499-A1 CAPREOMYCIN DERIVATIVES AND THEIR USE AS ANTIBACTERIALS ARRAY BIOPHARMA, INC. (US) 2006-05-18 WO disclosed
US-20060094644-A1 Capreomycin derivatives and their use as antibacterials ARRAY BIOPHARMA, INC. 2006-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203585-A1 CAPREOMYCIN DERIVATIVES AND THEIR USE AS ANTIBACTERIALS CAPRIN1, NISCH, RPIA MAPT 2831/4885TSHR 3596/4885HSD17B10 3074/4885
US-20060094644-A1 Capreomycin derivatives and their use as antibacterials SPOUT1, CAPRIN1, FBL MAPT 834/4885TSHR 3260/4885HSD17B10 3249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.